This revised application for postdoctoral training in pulmonary research at the University of Pittsburgh includes significant changes from our previous program including: a) highly focused programs based primarily in our basic science departments; b) reduction in number of positions requested by elimination of predoctoral positions; c) implementation of a three year research program; d) reorganization of recruitment and assessment of progress in which senior members of our basic science departments participate in administration of the program; e) exclusive emphasis on molecular and cellular biology of the lung as represented by current research interests in the Departments of Pharmacology and Cell Biology and Physiology; and f) potential for participation in therapeutic applications by trainee and investigator by interactions with Pittsburgh Genetics Institute (Gene Therapy) and Drug Discovery Programs (computational chemistry; peptidomimetic and other organic synthesis). The current proposal manifests a natural evolution of research opportunities between the Division of Pulmonary Allergy and Critical Care Medicine (Dr. Robert Rogers, PI) and the Department of Pharmacology (Dr. Bruce Pitt, Co-PI), and now includes new and broadened opportunities in the Department of Cell Biology and Physiology (Dr. Raymond Frizzell). While maintaining a strong broad-based research effort in human pathophysiology (including chronic obstructive airways disease, asthma, sleep, pulmonary transplantation medicine, epidemiology of respiratory medicine), we have restructured this research training program to provide intense exposure fob a limited number of fellows in basic principles of pharmacology and cell physiology as they apply to established lung related research programs at the University of Pittsburgh. Unique aspects of this training program include a commitment for a minimum of three years in research training including introduction to research mentors during their clinical year of fellowship, placement of research trainees exclusively into basic science departments, enrolling our fellows in didactic lectures intended for PhD-trained postdoctoral fellows, and confining the laboratory opportunities to two departments to assure our ability to assess the progress of these fellows. Broadbased intra- university support in Biotechnology, Drug Discovery and Computational Chemistry (via Departments of Molecular Genetics and Biochemistry, Pharmacology, Human Genetics, Cell Biology and Physiology, Surgery, and Chemistry) will provide opportunities to translate basic research in pulmonary biology to therapeutic applications including gene therapy of lung and novel synthetic derivatives to affect ion channel function and oncogene activity.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
5T32HL007563-14
Application #
2857642
Study Section
Research Training Review Committee (RTR)
Project Start
1984-07-01
Project End
2001-06-30
Budget Start
1999-07-01
Budget End
2000-06-30
Support Year
14
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Kitsios, Georgios D; Rojas, Mauricio; Kass, Daniel J et al. (2018) Microbiome in lung explants of idiopathic pulmonary fibrosis: a case-control study in patients with end-stage fibrosis. Thorax 73:481-484
Zank, Daniel C; Bueno, Marta; Mora, Ana L et al. (2018) Idiopathic Pulmonary Fibrosis: Aging, Mitochondrial Dysfunction, and Cellular Bioenergetics. Front Med (Lausanne) 5:10
Scheunemann, Leslie P; Khalil, Ramy; Rajagopal, Padma S et al. (2018) Development and Pilot Testing of a Simulation to Study How Physicians Facilitate Surrogate Decision-Making Based on Critically Ill Patients' Values and Preferences. J Pain Symptom Manage :
Rose, Jason J; Nouraie, Mehdi; Gauthier, Marc C et al. (2018) Clinical Outcomes and Mortality Impact of Hyperbaric Oxygen Therapy in Patients With Carbon Monoxide Poisoning. Crit Care Med 46:e649-e655
Hensley, Matthew K; Levine, Andrea; Gladwin, Mark T et al. (2018) Emerging therapeutics in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 314:L769-L781
Lennox, Alison T; Coburn, Stefanie L; Leech, John A et al. (2018) ATP12A promotes mucus dysfunction during Type 2 airway inflammation. Sci Rep 8:2109
Evankovich, John; Lear, Travis; Mckelvey, Alison et al. (2017) Receptor for advanced glycation end products is targeted by FBXO10 for ubiquitination and degradation. FASEB J 31:3894-3903
Meijles, Daniel N; Sahoo, Sanghamitra; Al Ghouleh, Imad et al. (2017) The matricellular protein TSP1 promotes human and mouse endothelial cell senescence through CD47 and Nox1. Sci Signal 10:
Weathington, Nathaniel M; Kanth, Shreya M; Gong, Qiaoke et al. (2017) IL-4 Induces IL17Rb Gene Transcription in Monocytic Cells with Coordinate Autocrine IL-25 Signaling. Am J Respir Cell Mol Biol 57:346-354
Gladwin, Mark T (2017) Translational Advances in the Field of Pulmonary Hypertension Bench to Bedside: How Fundamental Discoveries in Science Are Advancing Our Understanding and Therapy of Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 195:1-3

Showing the most recent 10 out of 114 publications